SillaJen unveils interim results of BAL0891 anticancer drug trial at European Society for Medical Oncology
Predicted impact: Low
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.
Predicted impact: Low
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.